Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | MPO | P05164 | 1/20 | 0.50 |
| ▸ | TPO | P07202 | 1/20 | 0.50 |
| ▸ | EPX | P11678 | 1/20 | 0.50 |
| ▸ | LPO | P22079 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 10/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29539478 | 1.00 | LTA4H (0.51) | LTA4HMPOTPOEPXLPO | |
| SCHEMBL29564176 | 0.85 | LTA4H (0.60) | LTA4HMPOTPOEPXLPO | |
| SCHEMBL28443559 | 0.84 | MAPT (0.57) | LTA4HMPOTPOEPXLPO | |
| SCHEMBL30086862 | 0.80 | MPO (0.47) | LTA4HMPOTPOEPXLPO | |
| SCHEMBL23888744 | 0.80 | MPO (0.47) | LTA4HMPOTPOEPXLPO | |
| SCHEMBL26013341 | 0.79 | ALDH1A1 (0.61) | LTA4HMPOTPOEPXLPO | |
| SCHEMBL5786732 | 0.78 | LTA4H (0.50) | LTA4H | |
| SCHEMBL1826466 | 0.78 | MAOA (0.56) | LTA4HMPOTPOEPXLPO | |
| SCHEMBL30876942 | 0.76 | LTA4H (0.51) | LTA4HMPOTPOEPXLPO | |
| SCHEMBL4470527 | 0.76 | CDK8 (0.56) | LTA4HMPOTPOEPXLPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092774-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-03-21 | — | — | US | disclosed |
| WO-2022057895-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-03-24 | — | — | WO | disclosed |
| US-7517992-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-7517992-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-7517992-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2009-04-14 | — | — | US | disclosed |
| EP-1534276-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2006-07-27 | — | — | US | disclosed |
| EP-1534276-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004021969-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092774-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | CYP2D6, CYP3A7, CYP2F1 | LTA4H 265/4885MPO 483/4885TPO 746/4885 |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR2H, POLR2E, POLR1E | LTA4H 3024/4885MPO 1022/4885TPO 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.